Clinigence Holdings ( (NUTX) ) has released a notification of late filing.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nutex Health Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. This delay is primarily due to the need to restate previous financial statements, including the Annual Report on Form 10-K (Yearly Report) for 2024 and the Quarterly Report on Form 10-Q (Quarter Report) for March 31, 2025. The company is working to complete these restatements before filing the delayed report. Nutex Health has received an extension from Nasdaq to file the June 30, 2025 Form 10-Q (Quarter Report) by December 12, 2025, to avoid delisting. The company anticipates significant changes in its financial results but has not provided specific estimates. Nutex Health is committed to resolving these issues promptly, with the notification signed by Jon C. Bates, Chief Financial Officer.
The most recent analyst rating on (NUTX) stock is a Buy with a $127.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Outperform.
NUTX’s strong financial performance and undervaluation are key strengths, supported by positive earnings call insights. However, increased leverage and reliance on arbitration revenue pose risks, warranting a cautious outlook.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 138,153
Technical Sentiment Signal: Buy
Current Market Cap: $595M
Find detailed analytics on NUTX stock on TipRanks’ Stock Analysis page.